ArticleScientific reports2025
Antibiofilm activity of ZnO-Ag nanoparticles against Pseudomonas aeruginosa.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- The role of nanoparticles in the treatment of diabetic foot ulcers: mechanisms, delivery platforms, translational challenges, and future directions.Discover nano · 2026Review
- Article
- Optimized green zinc oxide/chitosan/amoxicillin nanocomposite against Pseudomonas aeruginosa.Applied microbiology and biotechnology · 2026Article
- Green synthesis and antibacterial activity of zinc oxide nanoparticles usingRSC advances · 2026Article
- Mapping the knowledge landscape ofFrontiers in cellular and infection microbiology · 2026Review
- Strategies for biofilm inhibition: the role of synthetic drug- and nanotechnology-based agents.Archives of microbiology · 2025Review
- Design of Peptide-Modified Aluminum Nanoparticles with Enhanced Antimicrobial, Antibiofilm, Antioxidant, and DNA-Cleaving Properties.Pharmaceutics · 2025Article
- Smart hybrid nanomaterials for chronic infections: microbiome-responsive and sustainable therapeutic platforms.Journal of nanobiotechnology · 2025Review
- Antimicrobial Nanoparticles Against Superbugs: Mechanistic Insights, Biomedical Applications, and Translational Frontiers.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Biofilm-dispersal patterns in ESKAPE pathogens.Archives of microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Biofilm-related infections remain a major concern in clinical settings due to the increasing challenge of antimicrobial resistance to conventional antimicrobial treatments. Surface coatings of nanomaterials that can effectively prevent biofilm formation and disrupt established biofilms are essential to addressing this challenge. In this study, a ZnO-Ag nanocomposite was synthesized via a dry chemical method and characterized using XRD, XPS, TEM, SEM-EDX, and AFM, confirming the presence of highly crystalline and pure ZnO and Ag nanoparticles with sharp nanoscale features. The nanocomposite demonstrated potent antibiofilm activity against Pseudomonas aeruginosa, a common Gram-negative biofilm-forming pathogen. Surface-coated glass slides prevented initial biofilm formation, while treatment with higher nanocomposite concentrations (≥ 0.25 g/L) significantly disrupted pre-formed biofilms and altered biofilm architecture, as shown by SEM and crystal violet assays. Mechanistic investigations suggested that nanoparticle surface sharpness may contribute to membrane disruption, and EPR analysis confirmed the generation of reactive oxygen species (ROS), particularly superoxide and methyl radicals, under light exposure. These results highlight the composite's strong potential for integration into surfaces prone to bacterial colonization, offering a practical approach for reducing biofilm-related complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.